{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:02Z","timestamp":1791726362529,"version":"4.3.4"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2025,2,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              <jats:italic>Aspergillus fumigatus<\/jats:italic>\n              is a common cause of pulmonary and invasive mold infections among immunocompromised hosts. Mortality in immunocompromised hosts with invasive\n              <jats:italic>Aspergillus<\/jats:italic>\n              infections (IAI) has been reported to be as high as 80%. Therefore, appropriate therapy is essential in treating IAI. Both isavuconazole and voriconazole are first-line agents in treatment guidelines for IAI, but isavuconazole has favorable properties, often leading it to be preferred over voriconazole, given the lengthy duration of treatment. It is difficult to perform mold antifungal susceptibility testing, which often requires a reference lab and several weeks to determine results. Therefore, use of surrogate markers can be helpful to infer susceptibility when testing is not possible or delayed. We performed isavuconazole and voriconazole broth microdilution susceptibility testing by the Clinical and Laboratory Standards Institute (CLSI) method on a collection of 976 non-duplicate\n              <jats:italic>A. fumigatus<\/jats:italic>\n              isolates from a global surveillance program between 2017 and 2022. We found that voriconazole and isavuconazole have a very high essential agreement within two doubling dilutions at 99.9% and a categorical agreement of 92.7% with no very major errors, one major error (0.11%), and &lt;10% minor errors. Many of the minor errors were in the setting of voriconazole testing at a MIC of 0.5 mg\/L (susceptible) but isavuconazole at 2 mg\/L (intermediate). Genetic analysis of\n              <jats:italic>cyp51<\/jats:italic>\n              genes confirmed that isavuconazole and voriconazole susceptibility testing identified isolates with\n              <jats:italic>cyp51A<\/jats:italic>\n              and\n              <jats:italic>cyp51B<\/jats:italic>\n              mutations. Voriconazole can be used to predict the isavuconazole susceptibility testing result when\n              <jats:italic>A. fumigatus<\/jats:italic>\n              is tested by CLSI broth microdilution methodology.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/jcm.01207-24","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T14:00:30Z","timestamp":1734703230000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Use of voriconazole to predict susceptibility and resistance to isavuconazole for\n            <i>Aspergillus fumigatus<\/i>\n            using CLSI methods and interpretive criteria"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-5034","authenticated-orcid":true,"given":"Marisa L.","family":"Winkler","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley A.","family":"Fedler","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Karr","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-1543","authenticated-orcid":true,"given":"John H.","family":"Kimbrough","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","volume-title":"Manual of clinical microbiology","author":"Carroll KC","year":"2019","unstructured":"Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW. 2019. Manual of clinical microbiology. 12th ed. ASM Press, Washington, DC.","edition":"12"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01070-09"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","unstructured":"Pappas PG Alexander BD Andes DR Hadley S Kauffman CA Freifeld A Anaissie EJ Brumble LM Herwaldt L Ito J Kontoyiannis DP Lyon GM Marr KA Morrison VA Park BJ Patterson TF Perl TM Oster RA Schuster MG Walker R Walsh TJ Wannemuehler KA Chiller TM. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","DOI":"10.1086\/651262"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof2030021"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01141-23"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000662"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab444"},{"key":"e_1_3_4_12_2","volume-title":"M38 M51S Ed3. Performance standards for antifungal susceptibility testing of filamentous fungi","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. M38 M51S Ed3. Performance standards for antifungal susceptibility testing of filamentous fungi. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_13_2","unstructured":"Dufresne P Wiederhold N. 2023. CLSI antifungal susceptibility subcommittee working group update. January 20 2023."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00177-22"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01230-18"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13267"},{"key":"e_1_3_4_17_2","volume-title":"M23 Ed6. Development of In Vitro susceptibility test methods, breakpoints, and quality control parameters","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. M23 Ed6. Development of In Vitro susceptibility test methods, breakpoints, and quality control parameters. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02481-13"},{"key":"e_1_3_4_19_2","volume-title":"M52 Ed1. Verification of commercial microbial identification and antimicrobial susceptibility testing systems","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. M52 Ed1. Verification of commercial microbial identification and antimicrobial susceptibility testing systems. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx354"},{"key":"e_1_3_4_21_2","unstructured":"EUCAST. 2022. Breakpoint tables for interpretation of MICs and zone diameters version 12.0. Available from: www.eucast.org. Retrieved 1 May 2024."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.017"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt075"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70265-8"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac161"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2009.140142"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof9060608"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01207-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01207-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:08:01Z","timestamp":1743743281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01207-24"}},"subtitle":[],"editor":[{"given":"Daniel J.","family":"Diekema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,19]]}},"alternative-id":["10.1128\/jcm.01207-24"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01207-24","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"2024-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01207-24"}}